Testosterone therapy in men with prostate cancer: Literature review, clinical experience, and recommendations

Asian Journal of Andrology

Volumn 17, Issue 2, 2015, Pages 206-211

  Morgentaler, Abraham ^a   Conners, William P ^a  

^a Men's Health Boston   (United States)

Author keywords

androgen deprivation; androgens; hypogonadism; prostate cancer; prostate specific antigen; testosterone; testosterone therapy

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANDROGEN BLOOD LEVEL; ANDROGEN THERAPY; CANCER RADIOTHERAPY; FOLLOW UP; HUMAN; MALE; PATIENT SAFETY; PERSONAL EXPERIENCE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE VOLUME; PROSTATECTOMY; REVIEW; TREATMENT OUTCOME; ADVERSE EFFECTS; BLOOD; DEFICIENCY; DISEASE COURSE; EPIDEMIOLOGY; HORMONE SUBSTITUTION; PROSTATIC NEOPLASMS; RISK FACTOR; TUMOR RECURRENCE;

DISEASE PROGRESSION; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; TESTOSTERONE;

EID: 84924694363     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.148067     Document Type: Review

References (48)

1. Handelsman DJ. Global trends in testosterone prescribing, 2000-2011: expanding the spectrum of prescription drug misuse. Med J Aust 2013; 199: 548-51.
2. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 2006; 50: 935-9.
3. Khera M, Crawford D, Morales A, Salonia A, Morgentaler A. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol 2014; 65: 115-23.
4. Morgentaler A. Testosterone therapy in men with prostate cancer: scientific and ethical considerations. J Urol 2013; 189: S26-33.
5. Gooren LJ, Behre HM. Diagnosing and treating testosterone deficiency in different parts of the world: changes between 2006 and 2010. Aging Male 2012; 15: 22-7.
6. Endogenous Hormones and Prostate Cancer Collaborative Group, Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100: 170-83.
7. Zarotsky V, Huang MY, Carman W, Morgentaler A, Singhal PK, et al. Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. Andrology 2014; 2: 819-34.
8. Howden LM, Meyer JA. Age and Sex Composition 2010: 2010 Census Briefs; May, 2011. Available from: http://www.census.gov/prod/cen2010/briefs/c2010br-03.pdf. [Last accessed on 2014 Oct 26].
9. Traish AM, Miner MM, Morgentaler A, Zitzmann M. Testosterone deficiency. Am J Med 2011; 124: 578-87.
10. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7.
11. Fowler JE Jr, Whitmore WF Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981; 126: 372-5.
12. Prout GR Jr, Brewer WR. Response of men with advanced prostatic carcinoma to exogenous administration of testosterone. Cancer 1967; 20: 1871-8.
13. Morgentaler A. Testosterone replacement therapy and prostate cancer. Urol Clin N Am 2007; 34: 555-63.
14. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009; 55: 310-20.
15. Monath JR, McCullough DL, Hart LJ, Jarow JP. Physiologic variations of serum testosterone within the normal range do not affect serum prostate-specific antigen. Urology 1995; 46: 58-61.
16. Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med 1987; 317: 599-604.
17. Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004; 172: 1399-403.
18. Cooper CS, Perry PJ, Sparks AE, MacIndoe JH, Yates WR, et al. Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J Urol 1998; 159: 441-3.
19. Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, et al. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. Eur Urol 2012; 62: 757-64.
20. Klap J, Schmid M, Loughlin KR. The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy. J Urol 2014; [Epub Sept 28, 2014].
21. Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, et al. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. J Urol 2011; 186: 1005-11.
22. Rastrelli G, Corona G, Vignozzi L, Maseroli E, Silverii A, et al. Serum PSA as a predictor of testosterone deficiency. J Sex Med 2013; 10: 2518-28.
23. Morgentaler A, Benesh JA, Denes BS, Kan-Dobrosky N, Harb D, et al. Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months. J Sex Med 2014; 11: 2818-25.
24. Traish AM, Williams DF, Hoffman ND, Wotiz HH. Validation of the exchange assay for the measurement of androgen receptors in human and dog prostates. Prog Clin Biol Res 1988; 262: 145-60.
25. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006; 296: 2351-61.
26. Cui Y, Zong H, Yan H, Zhang Y. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2014; 17: 132-43.
27. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004; 172: 920-2.
28. Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005; 173: 533-6.
29. Khera M, Grober ED, Najari B, Colen JS, Mohamed O, et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med 2009; 6: 1165-70.
30. Pastuszak AW, Pearlman AM, Lai WS, Godoy G, Sathyamoorthy K, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol 2013; 190: 639-44.
31. Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 2007; 109: 536-41.
32. Morales A, Black AM, Emerson LE. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations. BJU Int 2009; 103: 62-4.
33. Pastuszak AW, Pearlman AM, Godoy G, Miles BJ, Lipshultz LI, et al. Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res 2013; 25: 24-8.
34. Balbontin FG, Moreno SA, Bley E, Chacon R, Silva A, et al. Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer. BJU Int 2014; 114: 125-30.
35. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126-31.
36. Ganz PA, Barry JM, Burke W, Col NF, Corso PS, et al. National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med 2012; 156: 591-5.
37. Klotz L. Active surveillance for prostate cancer: a review. Arch Esp Urol 2011; 64: 806-14.
38. Morgentaler A. Two years of testosterone therapy associated with decline in prostate-specific antigen in a man with untreated prostate cancer. J Sex Med 2009; 6: 574-7.
39. Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila D Jr, et al. Testosterone therapy in men with untreated prostate cancer. J Urol 2011; 185: 1256-60.
40. Morales A. Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry. BJU Int 2011; 107: 1369-73.
41. Mathew P. Prolonged control of progressive castration-resistant metastatic prostate cancer with testosterone replacement therapy: the case for a prospective trial. Ann Oncol 2008; 19: 395-6.
42. Leibowitz RL, Dorff TB, Tucker S, Symanowski J, Vogelzang NJ. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. BJU Int 2010; 105: 1397-401.
43. Ferreira U, Leitao VA, Denardi F, Matheus WE, Stopiglia RM, et al. Intermittent androgen replacement for intense hypogonadism symptoms in castrated patients. Prostate Cancer Prostatic Dis 2006; 9: 39-41.
44. Kaplan AL, Hu JC. Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes. Urology 2013; 82: 321-6.
45. Kaplan AL, Trinh QD, Sun M, Carter SC, Nguyen PL, et al. Testosterone replacement therapy following the diagnosis of prostate cancer: outcomes and utilization trends. J Sex Med 2014; 11: 1063-70.
46. Szmulewitz R, Mohile S, Posadas E, Kunnavakkam R, Karrison T, et al. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol 2009; 56: 97-103.
47. Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, et al. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol 2009; 56: 237-44.
48. Denmeade SR, Isaacs JT. Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. Prostate 2010; 70: 1600-7.